EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Beyond biomarkers: Exploring the diverse potential of a novel phosphoprotein in lung cancer management

Amirabbas Rostami iD, Ehsan Ranjbar, Somayeh Amiri, Fatemeh Ezzatifar iD

Journal of Cellular and Molecular Medicine · 2024

DOI: 10.1111/jcmm.70077 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Cellular and Molecular Medicine, 2024. Verfasst von Amirabbas Rostami und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran. Hauptthemen laut MEDLINE: Lung Neoplasms, Biomarkers, Tumor, Phosphoproteins, Nucleolin. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 99 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In addressing the challenges of lung cancer, attention has increasingly turned to molecular diagnostics and targeted therapies, with nucleolin (NCL) assuming a pivotal role, especially in non‐small cell lung cancer. The aberrant activity and cellular distribution of NCL act as crucial biomarkers for early detection and treatment monitoring, showing a strong correlation with disease progression and patient prognosis. Elevated NCL levels signal advanced disease and poorer outcomes, underscoring its significance in evaluating disease severity and therapeutic response. Strategies targeting the molecular interactions of NCL have spurred innovative approaches to inhibit tumour growth, overcome drug resistance and improve treatment efficacy. These advancements are paving the way for personalized therapies tailored to the unique molecular profiles of patients' tumours. Consequently, NCL stands at the forefront of lung cancer management, symbolizing the move towards more precise and individualized oncology care, and marking substantial progress in therapeutic development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsBiomarkers, TumorPhosphoproteinsNucleolinRNA-Binding ProteinsHumansCarcinoma, Non-Small-Cell LungPrognosisAnimalsMolecular Targeted Therapy

Stichwörter der Autor:innen

autoantibodydiagnosislung cancernucleolinprognosistherapy

Substanzen

Biomarkers, TumorPhosphoproteinsNucleolinRNA-Binding Proteins

Autor:innen und Institutionen

  • Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
  • Department of Urology, Uro-Oncology Research Center, Tehran University of Medical Sciences, Tehran, Iran.
  • Department of Microbiology, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
  • Department of Immunology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.

ORCID-Profile: Amirabbas Rostami, Fatemeh Ezzatifar

Zitieren

APA

Rostami, A., Ranjbar, E., Amiri, S., & Ezzatifar, F. (2024). Beyond biomarkers: Exploring the diverse potential of a novel phosphoprotein in lung cancer management. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.70077

Vancouver

Rostami A, Ranjbar E, Amiri S, Ezzatifar F. Beyond biomarkers: Exploring the diverse potential of a novel phosphoprotein in lung cancer management. Journal of Cellular and Molecular Medicine. 2024. doi:10.1111/jcmm.70077

BibTeX
@article{Rostami2024,
  author = {Rostami, Amirabbas and Ranjbar, Ehsan and Amiri, Somayeh and Ezzatifar, Fatemeh},
  title = {Beyond biomarkers: Exploring the diverse potential of a novel phosphoprotein in lung cancer management},
  journal = {Journal of Cellular and Molecular Medicine},
  year = {2024},
  doi = {10.1111/jcmm.70077}
}
Kostenlos starten →